SecBot SecBot
8-K ·Filed Mar 5, 2026

ZVSA

ZyVersa Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago SEC0001493152-26-008994
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

Monitor for future Qualified Offering above $15 million which would trigger favorable conversion terms for note holders and potentially lead to significant dilution. Watch for registration statements which would enable resale of underlying shares.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
ZVSA ▼ -34.62% at T+60d
NEUTRAL call -34.62% · α vs SPY -47.40% · entry $0.2600 → $0.1700
Entry = T+0 close
Mar 5, 2026
via day close
T+1d
-11.54%
call -11.54% · α -12.38%
$0.2300
settled 8mo ago
T+5d
-7.69%
call -7.69% · α -6.16%
$0.2400
settled 8mo ago
T+20d
-29.62%
call -29.62% · α -27.57%
$0.1830
settled 7mo ago
T+60d
-34.62%
call -34.62% · α -47.40%
$0.1700
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

ZyVersa Therapeutics raised $1 million through a private placement of convertible promissory notes and warrants to accredited investors. The notes bear 10% interest, mature in 12 months, and are convertible into common stock at a discount to future financing or market price, subject to a $0.02 floor. The warrants allow investors to purchase shares at a premium to future financing or market price, with registration rights for resale.

Key Financial Metrics

Deal Value
$1.0M
Deal Type
credit_facility

Key Facts

  • ZyVersa raised $1 million through issuance of convertible promissory notes and warrants
  • Notes bear 10% annual interest, mature in 12 months from issuance date
  • Notes convertible into common stock at 80% of Qualified Offering price or 80% of lowest 10-day VWAP, with $0.02 floor price
  • Warrants exercisable starting 6 months after issuance, expire after 5 years
  • Warrant exercise price set at 110% of Qualified Offering price or 110% of 5-day VWAP
  • Company must file resale registration statements for shares underlying notes and warrants
  • Proceeds to be used for working capital purposes

Financial Impact

$1 million in new debt financing with equity conversion features

debtdilutioncashFlow

Risk Factors

  • Potential significant dilution if company completes Qualified Offering
  • Default risk if company cannot repay notes at maturity
  • Downward pressure on stock price when registration statements become effective allowing resale

Market Snapshot

Exchange
OTC

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-008994
Exhibit: ex10-2.htm0001493152-26-008994
Exhibit: ex4-1.htm0001493152-26-008994
Document: form8-k.htm0001493152-26-008994
Document: 0001493152-26-008994-index-headers.html0001493152-26-008994
Document: 0001493152-26-008994-index.html0001493152-26-008994
Document: 0001493152-26-008994.txt0001493152-26-008994
2 reports for ZVSA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ZVSA — sortable, filterable
TypeNow
Jul 16, 2026
14w ago
8-K
BEARISH ★ 5/10
$0.1150 $0.0800▲ +30.43%▲ +35.38%$0.001000 (+99.13%)
Mar 5, 2026
33w ago
8-K
NEUTRAL ★ 4/10
$0.2600 $0.1700▼ −34.62%▼ −47.40%$0.001000 (−99.62%)
Showing 2 of 2

US Market Status

Market Open — Closes in 3h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026